Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Promis Neurosciences Inc

(TSX: PMN.TO)
Add to Portfolio
+0.01 (+5.00%)
as of Feb 19, 2020

Last 0.21
Change +0.01 (+5.00%)
Open 0.21
Prev. Close 0.20
Today's Range
0.21
0.21
52wk Range
0.17
0.44
Volume 103,481
Avg Volume 237,639

Perfomance Comparison

Name Today 3-Month 1-Year
PMN.TO +5.00% +5.00% -27.59%
$TXCX +0.38% +6.35% +12.47%
$TXCI +0.38% +6.31% +12.41%
DJIA +0.40% +6.03% +13.35%
S&P 500 +0.47% +8.62% +21.81%

Key Statistics

Annual EPS -0.03
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K 55,082
Weighted Alpha -28.07
Standard Deviation +1.18
Profit Margin -38,790.77%
Beta -1.55

Growth Rates

YTD +23.53%
1-Year -35.48%
3-Year +11.11%

Opinion

Sell Hold Buy

Recent Headlines

ProMIS Neurosciences to Participate in Noble Capital

Globe Newswire via COMTEX - Tue Feb 11, 06:30AM EST
Company to showcase its novel Alzheimer's, Parkinson's and ALS programs(full story)
PMN.TO: 0.21 (+0.01), ARFXF: 0.1526 (-0.0034)

ProMIS Neurosciences to Participate in the BIO CEO &

Globe Newswire via COMTEX - Thu Feb 06, 06:30AM EST
Company to showcase its novel Alzheimer's, Parkinson's and ALS programs(full story)
PMN.TO: 0.21 (+0.01), ARFXF: 0.1526 (-0.0034)

ProMIS Neurosciences Data for Alzheimer's Disease

GlobeNewswire via COMTEX - Wed Jan 29, 06:30AM EST
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,(full story)
PMN.TO: 0.21 (+0.01), ARFXF: 0.1526 (-0.0034)

ProMIS Neurosciences Appoints Dr. Jose Luis Molinuevo

GlobeNewswire via COMTEX - Wed Jan 15, 06:30AM EST
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,(full story)
PMN.TO: 0.21 (+0.01), ARFXF: 0.1526 (-0.0034)

ProMIS Neurosciences to present at Sachs 3rd Annual

Globe Newswire via COMTEX - Thu Jan 09, 06:30AM EST
Company to showcase its novel Alzheimer's, Parkinson's and ALS programs(full story)
PMN.TO: 0.21 (+0.01), ARFXF: 0.1526 (-0.0034)